Last week, Genentech, a member of the Roche Group, presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic SMA, aged from birth to 6 weeks. These data were presented at the 28th World Muscle Society (WMS) Congress.
Read more about the data presented here.
